PD-L1 inhibition by sparatlizumab improved effectivity of combined inhibition of BRAF and MEK with dabrafenib and trametinib in phase 2 clinical trial for colorectal cancer (Tian et al., 2023). Here, BRAF is linked to colorectal cancer.